Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2015-11-23 | Members of the Compensation Committee ... Jeff Himawan, Ph.D. ... Director Jeff Himawan, Ph.D., has declined to receive any compensation for his service as a director. |
| 2016-04-25 | Jeff Himawan, Ph.D. | 51 | Class II ... Compensation Committee and Audit Committee Member ... The current members of the Science and Technology Committee are Dr. Hill, Dr. De Souza and Dr. Himawan. ... Dr. Himawan has declined to receive any compensation for his service as a director. |
| 2017-01-12 | Directors and Named Executive Officers ... Jeff Himawan, Ph.D. 1,226,519 |
| 2017-05-18 | "Jeff Himawan, Ph.D. 52 Class II Director, Audit Committee Member and Compensation Committee Member" and "Dr. Himawan has declined to receive any compensation for his service as a director." |
| 2018-05-11 | "Jeff Himawan, Ph.D. ... 52 ... Audit Committee Member, Compensation Committee Member, Governance and Nominating Committee Chair and Science and Technology Committee Member" and "Dr. Himawan has declined to receive any compensation for his service as a director." |
| 2019-05-02 | Jeff Himawan, Ph.D. 54 II Governance and Nominating Committee Chair, Compensation Committee and Audit Committee Member, Science and Technology Committee Member ... Dr. Himawan has declined to receive any compensation for his service as a director. |
| 2020-05-01 | During 2019, the Governance and Nominating Committee consisted of Dr. Himawan, who served as Chairman, Mr. Lawlor, and Ms. Hunt. Dr. Himawan declined to receive any compensation for his service as a director. |
| Filing Date | Source Excerpt |
|---|---|
| 2006-04-13 | Dr. Himawan holds a B.S. in biology from the Massachusetts Institute of Technology and a Ph.D. in biological chemistry and molecular pharmacology from Harvard University. |
| 2006-09-08 | Jeff Himawan, Ph.D. |
| 2007-03-13 | Dr. Himawan holds a B.S. in biology from the Massachusetts Institute of Technology and a Ph.D. in biological chemistry and molecular pharmacology from Harvard University. |
| 2008-04-29 | Dr. Himawan holds a B.S. in biology from the Massachusetts Institute of Technology and a Ph.D. in biological chemistry and molecular pharmacology from Harvard University. |
| 2009-04-29 | Dr. Himawan holds a B.S. in biology from the Massachusetts Institute of Technology and a Ph.D. in biological chemistry and molecular pharmacology from Harvard University. |
| 2010-04-29 | Dr. Himawan holds a B.S. in biology from the Massachusetts Institute of Technology and a Ph.D. in biological chemistry and molecular pharmacology from Harvard University. Based on his background in corporate finance and capital raising and his extensive experiences in the biotechnology industry, the Board believes Dr. Himawan has the appropriate set of skills to serve as a member of our Board. |
| 2011-04-29 | Dr. Himawan holds a B.S. in biology from the Massachusetts Institute of Technology and a Ph.D. in biological chemistry and molecular pharmacology from Harvard University. |
| 2012-04-30 | Dr. Himawan holds a B.S. in biology from the Massachusetts Institute of Technology and a Ph.D. in biological chemistry and molecular pharmacology from Harvard University. Based on his background in corporate finance and capital raising and his extensive experiences in the biotechnology industry, the Board believes Dr. Himawan has the appropriate set of skills to serve as a member of our Board. |
| 2013-04-29 | Dr. Himawan holds a B.S. in biology from the Massachusetts Institute of Technology and a Ph.D. in biological chemistry and molecular pharmacology from Harvard University. |
| 2014-04-29 | Dr. Himawan holds a B.S. in biology from the Massachusetts Institute of Technology and a Ph.D. in biological chemistry and molecular pharmacology from Harvard University. |
| 2015-04-29 | Dr. Himawan holds a B.S. in biology from the Massachusetts Institute of Technology and a Ph.D. in biological chemistry and molecular pharmacology from Harvard University. |
| 2016-04-27 | Dr. Himawan holds a B.S. in biology from the Massachusetts Institute of Technology and a Ph.D. in biological chemistry and molecular pharmacology from Harvard University. |
| 2017-04-27 | Dr. Himawan holds a B.S. in biology from the Massachusetts Institute of Technology and a Ph.D. in biological chemistry and molecular pharmacology from Harvard University. |
| 2018-04-26 | Dr. Himawan holds a B.S. in biology from the Massachusetts Institute of Technology and a Ph.D. in biological chemistry and molecular pharmacology from Harvard University. Based on his background in corporate finance and capital raising and his extensive experience in the biotechnology industry, the Board believes Dr. Himawan has the appropriate set of skills to serve as a member of our Board. |
| 2019-04-26 | Dr. Himawan holds a B.S. in biology from the Massachusetts Institute of Technology and a Ph.D. in biological chemistry and molecular pharmacology from Harvard University. |
| 2020-04-27 | Dr. Himawan holds a B.S. in biology from the Massachusetts Institute of Technology and a Ph.D. in biological chemistry and molecular pharmacology from Harvard University. |
| 2021-04-27 | Dr. Himawan holds a B.S. in biology from the Massachusetts Institute of Technology and a Ph.D. in biological chemistry and molecular pharmacology from Harvard University. |
| 2022-04-26 | Jeff Himawan, Ph.D. has served on the board of directors of 12 different biotech/pharmaceutical companies (including four Nasdaq-listed companies) during the past 25 years. He holds a B.S. in biology from the Massachusetts Institute of Technology and a Ph.D. in biological chemistry and molecular pharmacology from Harvard University. Based on his background in corporate finance and capital raising and his extensive experience in the biotechnology industry, the Board believes Dr. Himawan has the appropriate set of skills to serve as a member of our Board. |
| 2023-04-26 | Dr. Himawan holds a B.S. in biology from the Massachusetts Institute of Technology and a Ph.D. in biological chemistry and molecular pharmacology from Harvard University. |
Source material: SEC submissions metadata and DEF 14A proxy filings from EDGAR. Last updated: 2026-05-06